The activated platelet is central to development of ischemic cardiovascular events. Guidelines recommend treatment with a P2Y12 receptor antagonist for 1-year after myocardial infarction (MI) to reduce the risk of recurrent events. The PEGASUS trial sought to determine the impact of using the P2Y12 antagonist ticagrelor as part of long-term therapy after MI. In this […]
Tag: acute myocardial infarction
Changing trends in AMI
Large series from around the Western world have consistently shown falling mortality and morbidity from cardiovascular disease but less information is available about age- and sex-specific outcomes and their changes in the recent past. […]
DES show mortality benefit in AMI
Currently both bare metal stents (BMS) and drug-eluting stents (DES) are used during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). PCI has been demonstrated to reduce the rate of death or recurrent ischaemia when compared to medical therapy. To date trials comparing DES and BMS in acute MI have been limited by small […]